Gentherm Lifts 2026 Outlook, Launches $400M Buyback, and Acquires Medical Device Maker
THRM sits 31% above its 52-week low of $27.
Summary
Gentherm posted record Q2 revenue, raised full-year guidance, authorized a new $400 million stock buyback, and acquired a medical device company—all while advancing its merger with Modine Performance Technologies.
Key Events · Earnings and Guidance · THRM
-
Record Q2 Revenue and Raised Guidance
Product revenues climbed 11% to a record $416.2 million, driving adjusted diluted EPS of $0.75. Full-year 2026 guidance was raised: revenue now $1.55B–$1.65B, adjusted EBITDA $185M–$200M, and adjusted free cash flow $85M–$100M.
-
New $400 Million Stock Buyback Authorized
The board terminated the existing $150 million repurchase program, which had $110.1 million remaining, and authorized a new $400 million buyback over three years, expiring July 27, 2029.
-
Medical Acquisition Expands Healthcare Portfolio
Gentherm acquired Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device, adding a complementary product and cross-selling opportunities in healthcare.
-
Merger with Modine Performance Technologies on Track
Key sign-to-close deliverables for the planned Reverse Morris Trust merger were completed; the transaction remains on track to close by early Q4 2026.
Analysis · THRM · Manufacturing
Record quarterly revenue of $416 million and a raised full-year outlook signal strong operational momentum. Underscoring confidence in cash generation, the board replaced a $150 million buyback program with a new $400 million authorization—a substantial capital return commitment. The acquisition of Innovative Medical Equipment broadens the healthcare portfolio with a complementary thermal therapy device. These moves come as the company progresses toward closing its transformative merger with Modine Performance Technologies, expected in early Q4 2026.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, THRM was trading at $35.50 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $27.00 to $39.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.